Table 2.

Targeting STAT3 in cancer therapy in clinical trials.

Drug/Molecular Pathway	Effect on STAT3	Clinical Trial Phase	Major Outcomes	Refs
AZD9150	Inhibition	Phase I	Anti-tumor activity in pre-clinical models and clinical trial	[76]
GRIM19	Inhibition	-	Sensitizing into radiotherapy	[79]
-	-	Phase I	STAT3 provides local progression	[81]
Nilotinib	Inhibition	Phase II	Diminution in cancer growth	[82]
OPB-31121	Inhibition	Phase I	High tolerance Inhibition of tumor growth	[83]